CLINICAL_TRIALS
trial_result
· 2020-09-17
Clinical Trial Update: A Study to Evaluate Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus (BEGIN) [Phase 3]
Summary
Phase 3 trial evaluating two doses of ocrelizumab in active systemic lupus erythematosus was terminated; results were posted later.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Genentech, Inc. | Conditions: Systemic Lupus Erythematosus | Phase 3 | Status: TERMINATED | Results posted: 2020-09-17